HRTS250117C27000
- 0.00
- 0.000.00%
Tema GLP-1, Obesity & Cardiometabolic ETF Newsroom
Obesity Drug Developer Metsera Files for $100M IPO
List of converted stocks (Part 2) [List of converted stocks for Parabolic Signal]
○ List of stocks that have switched to Sell market Code Stock Name Closing Price SAR Tokyo Main Board ＜1808＞ Haseko 1988 2059 ＜1835＞ East Steel 31753370 ＜1852＞ Asanuma Group 640677 ＜1887＞ Japan National Development 512527 ＜1898＞ Sekisui House 15051571 ＜1928＞ JGC HD 36033826 ＜1963＞ Fees 12681339 ＜2060＞ Fees
List of cloud break stocks (Part 2) [Ichimoku Kinko Hyo - List of cloud break stocks]
○ List of stocks that dropped below the clouds Market Code Name Closing Price Leading Span A Leading Span B Tokyo Main Board <1719> Ando Hazama 1153 1171.5 1158 <1814> Dai Sue Construction 1640 1641 1664.5 <1820> Nishimatsu Construction 5059 5090.2 55136.5 <1835> Toei Iron Works 3175 3205 3300 <1878> Daito Construction 16910 17007.5 17235 <
Wall Street Today: Market Turns Around, Let's See if it Lasts
Stocks Edge Down Ahead Of Key Inflation Reports, Crude Hits 5-Month High, Bitcoin Sinks: What's Driving Markets Monday?
What's Going On With CVS, Humana and UnitedHealth Shares Monday?
Thermo Fisher Scientific Analyst Ratings
The anti-obesity drug battle escalates! The CEO of Eli Lilly and Co reveals that the company's oral medication may be released early next year.
① Eli Lilly and Co's CEO David Ricks expects that its experimental oral weight-loss drug orforglipron will be approved as early as early 2026; ② The phase II trial data for orforglipron shows significant weight loss in participants, with clinical significance; ③ Although Eli Lilly and Co is once again trailing Novo-Nordisk A/S, its weight-loss injectable has completely surpassed semaglutide in head-to-head studies.
The Top and Bottom Contributors to S&P 500's Q4 EPS Growth
Live Stock News: Monday Market Falling, 'Too Big to Fail' Earnings to Start Q1 Report Season
Reported Earlier, Vertex Unveils Comprehensive Updates On CF, SCD, And Pipeline Progress Across Multiple Disease Areas For 2025
Earnings Week Ahead: JPM, BAC, C, GS, TSM, UNH and More
Can 2025 J.P. Morgan Healthcare Conference Spark Biotech M&A?
Key Deals This Week: FuboTV - Disney, Constellation Energy, Eli Lilly, Phillips 66, Intercontinental Exchange and More
CMS Proposes 4.33% Increase for Medicare Advantage Plans
Weekly Buzz: CES Came and Brought the Pain? That's Unexpected
Wall Street Today: Labor Gains Hurt a Hurting Market
Catalyst Watch: Bank Earnings, Oil Updates, Powerhouse Conferences in Retail and Healthcare
Lilly Signs Licensing Deal With Mediar for IPF Drug
"Eli Lilly In Advanced Talks To Buy U.S. Cancer Biotech For Up To $2.5B; Scorpion's Drug Candidate Inhibits A Mutation That Is A Major Driver Of Breast, Gynaecological And Head And Neck Cancers" - Financial Times